We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of Continuing Medical Education (CME) Insulin Program

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00824603
First Posted: January 19, 2009
Last Update Posted: December 2, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
International Diabetes Center at Park Nicollet
Eli Lilly and Company
Novo Nordisk A/S
United Health Care
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
HealthPartners Institute
  Purpose
The purpose of this study is to determine if a continuing medical education (CME) program can change primary care providers' use of insulin therapy - their confidence in selecting doses and engagement of patients in the decision making as to whether to initiate insulin therapy.

Condition
Diabetes

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Impact of CME Program on Self-Reported Confidence and Use of Insulin in Persons With Type 2 Diabetes

Resource links provided by NLM:


Further study details as provided by HealthPartners Institute:

Primary Outcome Measures:
  • We will determine whether attendees' self-reported confidence and use of insulin with persons with type 2 diabetes changes after they attend the CME program. [ Time Frame: pre program survey & 2-4 month post program survey ]

Secondary Outcome Measures:
  • pre-CME training level of patient's A1c when starting insulin therapy compared to post-CME training level of patient's A1c when starting insulin therapy [ Time Frame: pre program survey and 2-4 month post program survey ]

Enrollment: 294
Study Start Date: June 2006
Study Completion Date: August 2009
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
primary care provider
attending insulin CME Training

Detailed Description:

We will determine whether attendees' self-reported confidence and use of insulin with persons with type 2 diabetes changes after they attend the CME program. Specifically, we will address the following questions:

Question 1. Clinical guidelines. Is insulin initiated earlier (at a lower A1C)?

Question 2. Decision-making. Does confidence in selecting a starting insulin regimen change? Does confidence in selecting a starting insulin dose change? Does confidence in adjusting insulin change? Does confidence in discussion nutrition guidelines change?

Question 3. Application. Do more patients start using insulin? Who usually selects starting dose? How is starting dose selected? How often is insulin adjusted?

Question 4. Resources. How available are protocols for insulin use? How available is adequate time to monitor insulin therapy? How available is staff to teach insulin injections? How available is staff to help adjust insulin?

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   25 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Primary care providers affiliated with the participating healthcare organizations were invited to attend.
Criteria

Inclusion Criteria:

  • primary care provider attending CME training

Exclusion Criteria:

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00824603


Locations
United States, Minnesota
International Diabetes Center
Minneapolis, Minnesota, United States, 55416
Sponsors and Collaborators
HealthPartners Institute
International Diabetes Center at Park Nicollet
Eli Lilly and Company
Novo Nordisk A/S
United Health Care
Merck Sharp & Dohme Corp.
Investigators
Principal Investigator: Margaret Powers, PhD International Diabetes Center at Park Nicollet
  More Information

Responsible Party: HealthPartners Institute
ClinicalTrials.gov Identifier: NCT00824603     History of Changes
Other Study ID Numbers: 03425-06-C
First Submitted: January 15, 2009
First Posted: January 19, 2009
Last Update Posted: December 2, 2015
Last Verified: August 2013

Additional relevant MeSH terms:
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs